The global contrast
media agents market size is estimated to reach USD 5.96 billion by
2025, according to a new report by Grand View Research, Inc., expanding at a
CAGR of 3.8% during the forecast period. Increasing burden of chronic diseases
is augmenting diagnostic imaging procedure volumes, which is providing a fillip
to the market.
Competitive strategies, such as acquisitions and
indication extensions for existent products, adopted by players are expected to
trigger the growth of the market. The companies stirring changes in the space
is restricted to few in number. Among these, Guerbet, GE Healthcare, and Bayer
were the forerunners with top-selling drugs in their respective portfolios and
commanding more than 40% share in 2016. Bayer holds a prominent position in the
arena owing to its leading MRI agent, Gadavist/Gadovist, a macrocyclic
gadolinium agent. Guerbet is giving a stiff competition to its contemporaries
since it has joined forces with Mallinckrodt. The acquisition has led to a
streamlined portfolio of MRI and x-ray/CT contrast materials, which now hold
center position in this space. GE competes with Omnipaque and Visipaque as a
part of its suite of offerings, which account for nearly 12.0% market share.
Along with increasing incidence of chronic diseases,
rising demand and use of diagnostic imaging modalities is driven by
advancements in the underlying technologies. Equipment advancements include
innovation such as syringeless injectors, which help in achieving greater
accuracy in dose delivery, shorter examination time, and higher patient
throughput.
Regionally, North America will continue to dominate
the contrast media agents market throughout the forecast period. Presence of
well-established healthcare infrastructure, availability of advanced technologies
as well as recent launch of new contrast media agents for specific indications
are contributing to the growth of the region.
Browse full research report on Contrast Media Agents Market: https://www.grandviewresearch.com/industry-analysis/contrast-media-contrast-agents-market
Further
key findings from the report suggest:
- In 2016,
iodinated contrast agents registered the highest sales in the market due
to high penetration of contrast media agents in x-ray and CT procedures,
driven by availability of non-ionic stable iodinated agents for improved
diagnosis
- X-ray/CT
modality technique led the market in terms of revenue in 2016 due to its
wide acceptance and utilization in the market
- Gastrointestinal
applications are anticipated to register the fastest growth over the
forecast period due to regulatory approval of new products in the U.S.
market. For instance, Tagitol V was recently approved by the U.S. FDA for
use in adult patients undergoing CTC procedures
- On the
regional front, North America captured the highest revenue in 2016 owing
to presence of well-established healthcare infrastructure and availability
of advanced technologies
- Europe was
the second largest segment in 2016, attributable to increasing usage of
diagnostic imaging modalities such as MRI, CT, and ultrasound in the
region
- Key players
in this space are Bayer AG, GE Healthcare, Guerbet, Lantheus Medical
Imaging, and Bracco Diagnostics
- Most of the
key players are focusing on entering untapped regions and expanding their
product portfolios through mergers and acquisitions.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/healthcare
Grand
View Research has segmented the global contrast media agents market on the
basis of agent type, modality, application, and region:
Contrast
Media Agents Type Outlook (Revenue, USD Billion, 2016 - 2025)
- Iodinated
contrast media
- Barium-based
contrast media
- Gadolinium-based
contrast media
- Microbubble
contrast media
Contrast
Media Agents Modality Outlook (Revenue, USD Billion, 2016 - 2025)
- X-ray/CT
contrast agents
- MRI contrast
agents
- Ultrasound
contrast agents
Contrast
Media Agents Application Outlook (Revenue, USD Billion, 2016 - 2025)
- Cardiovascular
disorders
- Neurological
disorders
- Gastrointestinal
disorders
- Cancer
- Nephrological
disorders
- Musculoskeletal
disorders
- Others
Contrast
Media Agents Regional Outlook (Revenue, USD Billion, 2016 - 2025)
- North America
- U.S.
- Canada
- Europe
- U.K.
- France
- Asia
- Japan
- India
- Row
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment